CD8A and neoplasm: Regorafenib further augments this synergy by normalizing the tumor vasculature and immune microenvironment (23), while its inhibition of CSF1R and modulation of VEGFR2/3 promotes macrophage reprogramming and CD8+ T-cell activation, establishing a robust antitumor immune response.